Top Swiss firms pay respects to ‘formative’ business leader Fritz Gerber
Fritz Gerber worked for the Basel-based pharma giant for more than two decades, shaping Roche's development into a global healthcare firm.
Keystone / Markus Stuecklin
Pharmaceutical giant Roche and Zurich Insurance have paid their respects to business executive Fritz Gerber, who passed away on Sunday at the age of 91.
“Fritz Gerber was one of the most influential business leaders in Switzerland during a period of formative development for the country’s modern, open economy,” Zurich Insurance said in a statementExternal link on Monday.
Born on March 22, 1929, in Huttwil, canton Bern, Gerber worked for the insurance firm for almost 40 years, including 17 years as chief executive officer and 18 years as chairman of the board of directors.
“At Zurich, his leadership was characterized by a far-sightedness, a strategic mindset and an ability to bring out the best in people. He significantly contributed to Zurich’s strategic positioning and commercial success,” said Zurich Chairman Michel M. Liès.
Roche also describedExternal link Gerber as a “formative figure”. He worked for the Basel-based pharma giant for more than two decades shaping Roche’s development into a leading global healthcare company. He was Group CEO (1978-1998) and chairman of the board (1978-2001) and remained closely associated with the company as honorary chairman.
“Under his leadership, Roche’s Group structures were fundamentally renewed and decentralized– ranging from focusing on the core businesses to modernizing the capital structure. This created a fundamental change at Roche that still encourages entrepreneurial thinking today, and empowers employees to make their mark,” the firm said in a statement.
During his time at Roche, Gerber was behind biotechnology acquisitions such as the majority shareholding in Genentech at the beginning of the 1990s. He also led the takeover of Boehringer Mannheim, which ensured that Roche has become one of the world’s leading molecular and laboratory diagnostics groups.
More
More
Inside Roche: Taking on the tech sector
This content was published on
With its big bet on data and digitilisation, Roche has its eye on a new crop of specialists. Now it just needs to woo them.
Swiss government adopts three-pronged approach to end violence against women
This content was published on
Over the next few years, the federal government intends to take action against gender-based violence in three main areas.
Uri voters clear path for hotel and marina complex in central Switzerland
This content was published on
Voters in canton Uri in central Switzerland have rejected a Green Party initiative aimed at regulating the development of the lakeside site in Isleten.
Valais voters reject plan to achieve carbon neutrality by 2040
This content was published on
Voters in canton Valais in southern Switzerland have turned down a proposal for the region to achieve carbon neutrality by 2040.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
United States regulator approves Roche’s Covid-19 antibody test
This content was published on
The US Food and Drug Administration (FDA) has given emergency approval for use of the serological test developed by the Swiss pharma giant.
Roche boss who says bitter pill of truth is only way to build trust
This content was published on
Severin Schwan talks a lot about trust. Trust in people you live with, socialise with, work with. And trust is not won by being nice.
Are Big Pharma’s big innovation plans what we need?
This content was published on
Our analysis of what the biggest global companies in Switzerland are up to. This week: Big Pharma's R&D plans, coronavirus impact, and #cryptoleaks.
Swiss pharma giants swallow up start-ups in push for next big gene therapy
This content was published on
Swiss drug makers are increasingly relying on buying science rather than doing it themselves in the search for the next big medical breakthrough.
This content was published on
With its big bet on data and digitilisation, Roche has its eye on a new crop of specialists. Now it just needs to woo them.
This content was published on
The 300 richest people in Switzerland saw their fortunes increase by 4% overall in 2019, to reach CHF702 billion ($703 billion).
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.